ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new pill slow advanced breast cancer better than standard hormone therapy?
Disease control OngoingThis phase 3 trial is testing an experimental oral drug called imlunestrant, alone or combined with abemaciclib, against standard hormone therapies for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after prior hormone treatment. The study aims to se…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for advanced breast cancer: giredestrant trial shows promise
Disease control OngoingThis study tests a new drug called giredestrant in people with a type of advanced breast cancer (ER-positive, HER2-negative) that has progressed after prior treatments. About 303 participants will receive either giredestrant or another standard hormone therapy chosen by their doc…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outperform standard therapy for advanced breast cancer
Disease control OngoingThis Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for advanced breast cancer: early trial of oral drug LY3484356 begins
Disease control OngoingThis early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC